PN 78171
RN 00951 
AN 78248077
AU Platt-M-W.  Rao-G-J.  Nadler-H-L.
TI Reaction of 4-methylumbelliferylguanidinobenzoate with cultivated
   human skin fibroblasts derived from patients with cystic fibrosis.
SO Pediatr-Res. 1978 Aug. 12(8). P 874-7.
MJ BIOLOGICAL-ASSAY.  CYSTIC-FIBROSIS: en.  HYMECROMONE: du.
   PEPTIDE-HYDROLASES: me.  UMBELLIFERONES: du.
MN CELLS-CULTURED.  FIBROBLASTS: en.  GUANIDINES: du.  HUMAN.
   HYMECROMONE: aa.  SKIN: en.  SUPPORT-U-S-GOVT-P-H-S.
AB Protease activity in cultivated human skin fibroblasts has been
   quantitated using 4-methylumbelliferylguanidinobenzoate (MUGB), an
   active site titrant of trypsin-like proteases (7). The reaction of
   the proteases with MUGB was complete in 1 hr, inhibited both by
   benzamidine and (p-nitrophenyl)-p'-guanidinobenzoate, but not by p-
   hydroxymercuribenzoate. The extent of reaction was proportional to
   protein concentration and independent of MUGB concentration. This
   activity was present in the particulate fraction of the cell. The
   mean "titre" values (nanomoles of 4-methylumbelliferone released per
   mg protein) of the proteases in fibroblasts from eight controls (N),
   8 obligate heterozygotes (H), and 14 patients with cystic fibrosis
   (CF) were: N, 1.27 +/- 0.11; H, 0.82 +/- 0.12; CF, 0.66 +/- 0.10. The
   differences in the "titre" values for N:CF and N:H were significant
   (p less than 0.001) as were those for H:CF (p less than 0.01). The
   mean "titre" value obtained for cultivated control amniotic fluid
   cells was 1.29 +/- 0.17. These data indicate a reduction in the MUGB-
   reactive proteases in skin fibroblasts derived from patients with CF
   when compared either to control or to obligate heterozygotes. These
   data are consistent with our earlier suggestion (11, 15) that
   decreased proteolytic levels in the tissues and fluids of patients
   with CF may be a generalized phenomenon.
RF 001   BARRETT AJ            BIOCHEM J                      131   809 973
   002   BROWN CR              BIOCHEM J                      149   147 975
   003   CALLAHAN JW           PEDIATR RES                     11  1166 977
   004   CHASE T JR            BIOCHEM BIOPHYS RES COMMUN      29   508 967
   005   CHASE T JR            BIOCHEMISTRY                     8  2212 969
   006   HATCHER VB            BIOCHEM BIOPHYS RES COMMUN      76   602 977
   007   JAMESON GW            BIOCHEM J                      131   107 973
   008   KERR MA               BIOCHEMISTRY                    14  5088 975
   009   LOWRY OH              J BIOL CHEM                    193   265 951
   010   NADLER HL             NATURE                         213  1261 967
   011   WALSH-PLATT M         AM J HUM GENET                  29  111A 977
   012   RAO GJS               J PEDIATR                       80   573 972
   013   RAO GJS               PEDIATR RES                      8   684 974
   014   RAO GJS               PEDIATR RES                      9   739 975
CT   1   BROCK DJH             LANCET                           1  1245 979
     2   WALSH MM              LANCET                           1   622 979
     3   HARRIS A              DEVELOP MED CHILD NEUROL        21   675 979
     4   WALSHPLATT M          ENZYME                          24   224 979
     5   NADLER HL             LANCET                           2    96 980
     6   NADLER HL             PEDIATRICS                      66   690 980
     7   WALSH MMJ             AM J OBSTET GYNECOL            137   978 980
     8   TUMMLER B             CLIN CHIM ACTA                 125   219 982
     9   GREEN JR              EUR J PEDIATR                  139    35 982
    10   BROCK DJH             PRENAT DIAGN                     3     1 983
    11   BRIDGES MA            ANN NY ACAD SCI                421   360 983
    12   CEDER O               ACTA PAEDIATR SCAND           1983     1 983
    13   BUYS CHCM             CLIN CHIM ACTA                 136   229 984